FDA approves N30 Pharma's NDA for N6022 GSNOR

N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration.  N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).  

N30 Pharma will now begin a first-in-man, Phase 1, dose escalation trial of N6022 in healthy subjects.  The trial will assess the safety profile, tolerability and pharmacokinetics of single intravenous doses of N6022.